One To Watch

3T Biosciences

A discovery-stage biotechnology company developing next-generation T-cell receptor (TCR)–based immunotherapies for cancer. 3T Biosciences combines machine learning, large-scale antigen libraries and experimental immunology to identify new targets and engineer TCR-based therapeutics for solid tumors and other immune-mediated diseases.

Company Overview

3T Biosciences focuses on discovering novel tumor antigens and designing T-cell receptor–based therapies capable of recognizing and destroying cancer cells. The company’s strategy addresses a major bottleneck in cancer immunotherapy: identifying safe and broadly applicable targets for solid tumors.

Its platform integrates computational methods with experimental immunology to map immune recognition of tumor antigens and generate therapeutically relevant TCRs.

Headquarters and Global Presence

3T Biosciences is headquartered in South San Francisco, California.

The company operates as a discovery-stage biotech, conducting research and development internally while collaborating with pharmaceutical partners for broader development opportunities.

Founding and History

3T Biosciences was founded in 2017 based on research originating from the laboratory of structural biologist K. Christopher Garcia at Stanford University.

The company has raised venture financing from investors including Westlake Village BioPartners, Lightspeed Venture Partners and CRV to support platform development and early pipeline work.

Therapy Areas and Focus

The company’s research primarily targets oncology, particularly solid tumors that have historically responded poorly to existing immunotherapies.

Additional areas of investigation include:

Immune-mediated diseases
Potential infectious disease applications where immune recognition can be therapeutically exploited

Technology Platforms and Modalities

3T Biosciences’ core technology is the 3T-TRACE platform, which combines machine learning with large antigen libraries to identify T-cell receptor targets and engineer therapeutic TCR candidates.

The platform aims to discover tumor-specific antigens and generate TCR-based therapies or TCR mimetics with improved specificity and safety profiles.

Key Personnel

Stefan Scherer, Chief Executive Officer
Marvin Gee, Co-Founder and Vice President, Head of Target Discovery
Leah Sibener, Co-Founder

Strategic Partnerships

3T Biosciences has entered into collaborations with pharmaceutical partners to develop T-cell–based immunotherapies, including agreements with Boehringer Ingelheim to identify and develop novel cancer targets.

These partnerships aim to translate discoveries from the company’s target discovery platform into therapeutic development programs.

FAQ Section

3T Biosciences develops immunotherapies based on T-cell receptors. Its research focuses on identifying tumor antigens that can be safely targeted by engineered immune cells.

The primary focus is solid tumors, with exploratory work in other immune-related diseases.

The proprietary 3T-TRACE platform uses machine learning and large antigen libraries to discover TCR targets and design therapeutics.

3T Biosciences operates at the discovery and preclinical stage, focusing on target identification and early therapeutic design.

The company was founded by Leah Sibener and Marvin Gee, building on research from Stanford scientist K. Christopher Garcia.

Yes. The company has partnered with Boehringer Ingelheim to develop next-generation T-cell immunotherapies.

Key milestones include identification of clinically viable TCR targets, advancement of lead programs into preclinical development and potential entry into first-in-human clinical studies.

Want to Update your Company's Profile?